 |
|
|
prIME Oncology invites you to view CME-certified prIME Downloadable Slides that focus on new oncology data just released from the 51st American Society of Hematology Annual Meeting and Exposition
prIME Downloadable Slides from the 51st American Society of Hematology Annual Meeting and Exposition
To access the slides, please read the Continuing Medical Education information below.
|
Release Date
December 31, 2009
|
Expiration Date
December 31, 2010 |
Estimated Time to Complete Activity
3.75 hours
|
Media
Internet |
Target Audience
This educational activity is intended for hematologists/oncologists, pharmacists, and oncology nurses actively involved in the management of hematologic malignancies.
|
Overview
These downloadable slides are based on recently released data from the 51st American Society of Hematology Annual Meeting and Exposition, focusing on various aspects of the management of patients with hematologic malignancies. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the latest management approaches for hematologic malignancies including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative disorders
- Evaluate difficult or unusual problems encountered by the practicing hematologist/oncologist
- Identify appropriate management options based on emerging data
- Discuss issues surrounding the design and conduct of clinical trials that incorporate novel agents and/or regimens for patients with hematologic malignancies
- Summarize emerging data in the management of multiple hematologic malignancies and integrate new findings into clinical practice
|
Sponsorship Statement
This activity is jointly sponsored by Postgraduate Institute for Medicine and prIME Oncology. |
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute of Medicine is accredited by the ACCME to provide continuing medical education for physicians. |
Credit Designation Statement
Postgraduate Institute of Medicine designates this educational activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period December 2009 through December 31, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.
You may complete the post-test online at http://www.cmeuniversity.com. On the navigation menu, click on "FIND POST-TEST/EVALUATION BY COURSE". Search by Course ID. Upon successfully completing the post-test and evaluation, your certificate will be made available immediately.
Chronic Lymphocytic Leukemia: 6868
Multiple Myeloma: 6991
Non-Hodkin Lymphoma: 6992
Various Hematologic Topics: 6993
|
Support Statement
This activity is supported by educational grants from Genentech BioOncology; GlaxoSmithKline; Millennium Pharmaceuticals, Inc., The Takeda Oncology Company; and sanofi-aventis. |
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of
interest with its instructors, planners, managers and other individuals
who are in a position to control the content of CME activities. All
relevant conflicts of interest that are identified are thoroughly
vetted by PIM for fair balance, scientific objectivity of studies
utilized in this activity, and patient care recommendations. PIM is
committed to providing its learners with high quality CME activities
and related materials that promote improvements or quality in
healthcare and not a specific proprietary business interest of a
commercial interest.
The following planners and managers of Postgraduate Institute for Medicine, Linda
Graham, RN, BSN, BA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD;
Julia Kirkwood, RN, BSN; and Jan Schultz, RN, MSN, CCMEP hereby
state that they or their spouse/life partner do not have any financial
relationships or relationships to products or devices with any
commercial interest related to the content of this activity of any
amount during the past 12 months.
The following planners and managers of prIME Oncology, Kathryn Brown, PhD (editorial), Trudy Stoddert, ELS (editorial), and
Susan Ahn (project management) hereby state that they or their
spouse/life partner do not have any financial relationships or
relationships to products or devices with any commercial interest
related to the content of this activity of any amount during the past
12 months.
|
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Postgraduate Institute for Medicine, prIME Oncology, and the supporters of this acivity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, prIME Oncology, or the supporters of this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
|
|
For questions regarding this activity, please contact:
Postgraduate Institute of Medicine
(303) 799 1930
Email: Information@pimed.com
Web: www.pimed.com
|
|
|
|
|
|
|
|
|
|
|
|
